GAMMA Investing LLC Purchases 6,215 Shares of Haleon plc (NYSE:HLN)

GAMMA Investing LLC raised its holdings in shares of Haleon plc (NYSE:HLN) by 41.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,258 shares of the company’s stock after acquiring an additional 6,215 shares during the period. GAMMA Investing LLC’s holdings in Haleon were worth $203,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in HLN. FMR LLC boosted its stake in shares of Haleon by 5.8% in the 3rd quarter. FMR LLC now owns 104,918,269 shares of the company’s stock valued at $1,110,035,000 after purchasing an additional 5,768,117 shares in the last quarter. Sculptor Capital LP boosted its position in Haleon by 67.8% during the second quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock valued at $73,407,000 after buying an additional 3,592,000 shares during the period. Clearbridge Investments LLC grew its stake in shares of Haleon by 8.6% during the second quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company’s stock valued at $344,888,000 after buying an additional 3,307,009 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Haleon by 49.9% in the third quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock worth $96,833,000 after buying an additional 3,046,841 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Haleon by 25.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock valued at $53,791,000 after acquiring an additional 1,026,939 shares during the period. 6.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on HLN shares. Morgan Stanley lifted their price target on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research note on Friday, September 20th. UBS Group upgraded shares of Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $10.95.

Haleon Price Performance

Shares of HLN stock opened at $9.47 on Wednesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon plc has a fifty-two week low of $7.89 and a fifty-two week high of $10.80. The firm has a market cap of $42.87 billion, a P/E ratio of 27.85, a P/E/G ratio of 2.95 and a beta of 0.29. The business’s 50 day moving average price is $9.62 and its 200-day moving average price is $9.67.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.